SUPERNUS PHARMACEUTICALS, INC. Payments of Financing Costs
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Payments of Financing Costs of $3.63 million for the 12-month period ending 2013-12-31, per its 10-K/A filed 2017-01-20.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2017-01-20
- SUPERNUS PHARMACEUTICALS, INC. payments of financing costs for the quarter ending 2013-12-31 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payments of financing costs for the quarter ending 2013-09-30 was $29.00K, a 81.25% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payments of financing costs for the quarter ending 2013-06-30 was $3.47M, a 57.65% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payments of financing costs for the quarter ending 2013-03-31 was $125.00K, a 81.32% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payments of financing costs for fiscal 2013 was $3.63M, a 39.99% decline from fiscal 2012.
- SUPERNUS PHARMACEUTICALS, INC. payments of financing costs for fiscal 2012 was $6.04M, a 519.90% increase from fiscal 2011.
- SUPERNUS PHARMACEUTICALS, INC. payments of financing costs for fiscal 2011 was $975.00K, a 27.51% decline from fiscal 2010.
- SUPERNUS PHARMACEUTICALS, INC. payments of financing costs for fiscal 2010 was $1.34M.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-01-20 | $29.00K derived: sum of 2 quarters · filed 2017-01-20 | $3.50M derived: sum of 3 quarters · filed 2017-01-20 | $3.63M 10-K/A · filed 2017-01-20 |
| 2013-09-30 | $29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $3.50M derived: sum of 2 quarters · filed 2014-11-12 | $3.63M 10-Q · filed 2014-11-12 | $6.78M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | $3.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $3.60M 10-Q · filed 2014-08-12 | $6.75M derived: sum of 3 quarters · filed 2015-03-12 | $6.77M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | $125.00K 10-Q · filed 2014-05-13 | $3.28M derived: sum of 2 quarters · filed 2015-03-12 | $3.30M derived: sum of 3 quarters · filed 2015-03-12 | $5.50M derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | $3.16M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $3.17M derived: sum of 2 quarters · filed 2015-03-12 | $5.38M derived: sum of 3 quarters · filed 2015-03-12 | $6.04M 10-K · filed 2015-03-12 |
| 2012-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $2.22M derived: sum of 2 quarters · filed 2013-11-13 | $2.89M 10-Q · filed 2013-11-13 | $3.16M derived: sum of 4 quarters · filed 2014-03-21 |
| 2012-06-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | $2.87M 10-Q · filed 2013-08-14 | $3.14M derived: sum of 3 quarters · filed 2014-03-21 | $3.18M derived: sum of 4 quarters · filed 2014-03-21 |
| 2012-03-31 | $669.00K 10-Q · filed 2013-05-15 | $939.00K derived: sum of 2 quarters · filed 2014-03-21 | $974.00K derived: sum of 3 quarters · filed 2014-03-21 | $988.00K derived: sum of 4 quarters · filed 2014-03-21 |
| 2011-12-31 | $270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | $305.00K derived: sum of 2 quarters · filed 2014-03-21 | $319.00K derived: sum of 3 quarters · filed 2014-03-21 | $975.00K 10-K · filed 2014-03-21 |
| 2011-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | $49.00K derived: sum of 2 quarters · filed 2012-11-02 | $705.00K 10-Q · filed 2012-11-02 | |
| 2011-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | $670.00K 10-Q · filed 2012-08-13 | ||
| 2011-03-31 | $656.00K 10-Q · filed 2012-06-08 | |||
| 2010-12-31 | $1.34M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |